OKYO Pharma Limited (OKYO) Monday said Phase 2 study of OK-101 ophthalmic solution in patients with dry eye disease did not meet its primary goal.
However, a statistically significant improvement was observed in both a sign endpoint of total conjunctival staining and two symptoms endpoints of dry eye disease, burning/stinging and blurred vision, the company said in a statement.
According to OKYO Pharma, this first-in-human trial of OK-101 established a clear and informed path for further development in Phase 3 registration trials.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.